Cmed Shows How Encapsia Provides Live, Actionable Data Insights In Oncology Clinical Trials At The 2017 ASCO Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)--Cmed, an innovative, technology-led oncology CRO, today announced it will be exhibiting at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois (June 3-5), and showing how encapsia® can help improve patient safety, study conduct and decision making in oncology clinical trials (Booth 23128).

Cmed has earned a strong reputation for successfully conducting oncology trials across all phases and in numerous cancer types, including breast, lung, prostate, colorectal and other solid cancers, and haematological malignancies. This experience now coupled with encapsia®, a proven new generation clinical data suite already used by some big and small Biopharma Sponsors, enables Cmed to provide its Sponsors with previously unheard of ability to collect, review, decide and take actions on their clinical trial data.

Visitors are invited to join Cmed at booth 23128 to see live demonstrations of the benefits encapsia® brings to oncology trials and learn more about how other Sponsors are benefiting.

To schedule a meeting with the Cmed team during ASCO 2017, contact Patrick Maloney, Director of Business Development at pmaloney@cmedresearch.com, or Jessi Lanuza, Associate Director of Business Development at jlanuza@cmedresearch.com.

About Cmed

Cmed is an innovative, full service technology-led CRO. Cmed brings together experienced people and technology, providing customers with a friendly, proactive service, and delivers this service using advanced clinical data capture, management and reporting software and processes. Cmed’s new generation clinical data suite, encapsia™, streamlines the capture, management and reporting of clinical data, saving customers time and money. Clinical data can be captured flexibly by eSource, multi-media and web eDC, while being displayed in live visual insights, providing live analytics, and allowing within suite audit trailed actions. It is fully compliant with regulatory guidelines, and allows integration with existing systems. For more information visit www.cmedresearch.com.